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Abstract
Background: Addition of high-dose cytarabine (HDCA) to the conventional cyclophosphamide/total-body irradiation
(CY/TBI) regimen significantly improved prognosis after cord blood transplantation (CBT) for adult acute myelogenous
leukemia (AML) and myelodysplastic syndrome (MDS). The efficacy of HDCA in bone marrow or peripheral blood stem
cell transplantation (BMT/PBSCT), however, has not yet been elucidated.
Findings: We conducted a cohort study to compare the prognosis of HDCA/CY/TBI (N = 435) and CY/TBI (N = 1667) in
BMT/PBSCT for AML/MDS using a Japanese transplant registry database. The median age was 38 years, and 86.0 % of
the patients had AML. Unrelated donors comprised 54.6 %, and 63.9 % of donors were human leukocyte antigen
(HLA)-matched. Overall survival (OS) was not improved in the HDCA/CY/TBI group (adjusted hazard ratio (HR),
1.14; p = 0.13). Neutrophil engraftment was inferior (HR, 0.80; p < 0.01), and the incidence of hemorrhagic cystitis
and thrombotic microangiopathy increased in HDCA/CY/TBI (HR, 1.47 and 1.60; p = 0.06 and 0.04, respectively), leading
to significantly higher non-relapse mortality (NRM; HR, 1.48; p < 0.01). Post-transplant relapse and tumor-related mortality
were not suppressed by the addition of HDCA.
Conclusions: This study indicated the inefficacy of HDCA/CY/TBI in BMT/PBSCT for AML/MDS. Our results should be
validated in large-scale prospective studies.
Introduction
Cyclophosphamide/total-body irradiation (CY/TBI) is a
widely known conventional myeloablative regimen in
allogeneic hematopoietic cell transplantation (HCT) for
adult acute myelogenous leukemia (AML) and myelo-
dysplastic syndrome (MDS) [1–3], while regimens with
stronger anti-leukemic effects have been sought to re-
duce post-transplant relapse [4]. Among them, the
addition of high-dose cytarabine (HDCA) to CY/TBI
may be promising; in our recent large-scale study,
HDCA/CY/TBI significantly improved overall survival
(OS) compared to CY/TBI by suppressing relapse with-
out increasing severe adverse events or non-relapse mor-
tality (NRM) in cord blood transplantation (CBT) for
AML/MDS [5]. However, previous studies in a small co-
hort with mixed hematopoietic malignancies showed
that HDCA/CY/TBI increased NRM after bone marrow
transplantation (BMT) [6, 7]. These results require valid-
ation using disease-specified and newer cohorts, in order
to reflect the characteristics of each malignancy and the
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Table 1 Patient characteristics
Variables Total CY/TBI HDCA/CY/TBI
N = 2102 % N = 1667 % N = 435 % p
Sex Male 1205 57.3 959 57.5 246 56.5
Female 897 42.7 708 42.5 189 43.5 0.71
Age Median (years) 38 38 38 0.10
(Range) (16–64) (16–62) (16–64)
≤49 1762 83.8 1391 83.4 371 85.3
≥50 340 16.2 276 16.6 64 14.7 0.35
PS 0–1 1963 93.3 1577 94.6 386 88.7
≥2 104 5.0 62 3.7 42 9.7
Unknown 35 1.7 28 1.7 7 1.6 <0.01*
HCT-CI ≤2 1287 61.2 1024 61.4 263 60.5
≥3 111 5.3 90 5.4 21 4.8
Unknown 704 33.5 553 33.2 151 34.7 0.78
CMV sero-status Negative 392 18.7 312 18.7 80 18.4
Positive 1524 72.4 1221 73.3 303 69.6
Unknown 186 8.9 134 8.0 52 12.0 0.04*
Diagnosis AML 1808 86.0 1397 83.8 411 94.5
MDS 294 14.0 270 16.2 24 5.5 <0.01*
Disease risk Standard 1276 60.7 1074 64.4 202 46.4
High 826 39.3 593 35.6 233 53.6 <0.01*
(In AML) Standard 1191 65.9 993 71.1 198 48.2
High 617 34.1 404 28.9 213 51.8 <0.01*
(In MDS) Standard 85 28.9 81 30.0 4 16.7
High 209 71.1 189 70.0 20 83.3 0.17
Days from diagnosis to HCT Median 239 240 237 0.03*
≤240 1056 50.2 834 50.0 222 51.0
≥241 1046 49.8 833 50.0 213 49.0 0.71
Donor source Rel-BM 455 21.7 351 21.1 104 23.9
Rel-PB 499 23.7 386 23.2 113 26.0
UR-BM 1148 54.6 930 55.7 218 50.1 0.11
Graft cell dose BM (NCC, median) 2.69 × 108/kg 2.66 × 108/kg 2.77 × 108/kg 0.27
PB (CD34+ cell count, median) 3.99× 106/kg 4.00× 106/kg 3.67× 106/kg 0.52
HLA mismatch Matched 1343 63.9 1057 63.4 286 65.7
Mismatched 759 36.1 610 36.6 149 34.3 0.37
Sex mismatch Matched 1145 54.4 919 55.1 226 51.9
M to F 508 24.2 398 23.9 110 25.3
F to M 445 21.2 346 20.8 99 22.8
Unknown 4 0.2 4 0.2 0 0.0 0.45
ABO mismatch Matched 1114 53.0 888 53.3 226 52.0
Minor 389 18.5 305 18.3 84 19.3
Major 354 16.8 287 17.2 67 15.4
Both 186 8.9 148 8.9 38 8.7
Unknown 59 2.8 39 2.3 20 4.6 0.12
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recent progress in supportive therapies, such as antibi-
otics. Therefore, we performed a cohort study to com-
pare prognosis following HDCA/CY/TBI and CY/TBI in
AML/MDS patients who underwent BMT or peripheral
blood stem cell transplantation (PBSCT), using the Japa-
nese transplant registry database.
Patients and methods
Data for adult patients (age ≥16 years) with AML and
MDS who underwent allogeneic BMT or PBSCT from re-
lated (Rel) or unrelated (UR) donors as first HCT after CY/
TBI (CY, total 120 mg/kg; TBI, 10–12 Gy) or HDCA/CY/
TBI (CA, 2–3 g/m2 twice a day for 2–3 days) [5] between
January 1, 2000 and December 31, 2012, were obtained
from the Japanese Transplant Registry Unified Manage-
ment Program (TRUMP) [8]. UR-PBSCT and haploidenti-
cal HCT were not included because of the small number
of patients. Donor-derived serum and/or erythrocytes were
depleted from grafts in case of mismatched ABO blood
type, and grafts were transplanted without T cell depletion.
Our protocol complied with the Declaration of Helsinki,
and it was approved by the TRUMP Data Management
Committee and the Ethics Committee of Kyoto University.
Each patient provided written informed consent.
From the registry database, we extracted data on basic
pre-transplant characteristics and post-transplant clinical
courses. Disease risk was defined as previously reported
[9]. Disparity in human leukocyte antigen (HLA)-A, B, and
DR antigens was determined at the serologic level in Rel-
BMT and Rel-PBSCT. In UR-BMT, 8 antigens including
HLA-C were determined at the allele level; a 6/6 (Rel) or
8/8 (UR) match was considered HLA-matched [10]. Statis-
tical analyses were performed as described previously [5].
Results
We evaluated 2102 patients who underwent HCT with
CY/TBI (N = 1667) or HDCA/CY/TBI (N = 435), with a
median follow-up of 1134 days (range, 40–4947 days).
Patients with AML and high-risk disease were condi-
tioned more frequently with HDCA/CY/TBI (Table 1).
The dose of TBI was not different between CY/TBI and
HDCA/CY/TBI (10 Gy, 4.5 vs 4.3 %; 12 Gy, 95.1 vs
94.3 %, respectively); 12 Gy was divided into 4 (26.1 vs
34.1 %) or 6 fractions (70.2 vs 60.9 %). Graft-versus-host
disease (GVHD) prophylaxis composed of cyclosporine
(49.1 %) or tacrolimus (50.9 %), most of which (more
than 96 %) were combined with methotrexate. No differ-
ence was observed between the two groups.
OS of the HDCA/CY/TBI group was inferior to that of
the CY/TBI group (Fig. 1a; 59.3 vs 72.0 % at 1 year; 45.3 vs
58.8 % at 3 years after HCT). This difference was significant
on univariate analysis (Table 2), but not on multivariate
analysis after adjustment for confounding factors (hazard
ratio (HR), 1.14; p = 0.13; Table 3). In subgroup analyses ac-
cording to pre-transplant characteristics, OS in the HDCA/
CY/TBI group was significantly inferior in standard-risk
disease (HR, 1.52; p < 0.01). No significant differences were
found in other subgroups (Additional file 1: Figure S1).
Relapse, tumor-related mortality, and NRM were cal-
culated; relapse was not reduced by HDCA addition
(HR, 0.90; 95 % confidence interval (CI), 0.63–1.30;
p = 0.58), resulting in unmitigated tumor-related mor-
tality in the HDCA/CY/TBI group (Fig. 1b and
Table 3) regardless of disease risk (high risk: HR, 0.91;
p = 0.47; standard risk: HR, 0.84; p = 0.46). On the other
hand, HDCA/CY/TBI significantly increased NRM in
the whole cohort (HR, 1.48; p < 0.01; Fig. 1c and
Table 3) especially in the acute phase after HCT. The
major causes of NRM included organ failure, infection,
and GVHD, without significant differences between the
two groups (Table 4).
We compared the clinical courses that led to higher
NRM in HDCA/CY/TBI, with a focus of engraftment,
GVHD, infection, and other acute phase complications
(Fig. 2). The HDCA/CY/TBI group showed significantly
lower proportions of neutrophil and platelet engraft-
ment following HCT (HR, 0.80; p < 0.01, and HR, 0.83;
p < 0.01, respectively). Complete chimerism was achieved
in 78.2 % of the CY/TBI group vs 72.6 % of the HDCA/
CY/TBI group (p = 0.04). We observed no significant dif-
ferences in the incidence of acute or chronic GVHD
(grades II–IV acute GVHD, 39.3 vs 38.2 %; chronic GVHD
Table 1 Patient characteristics (Continued)
GVHD prophylaxis CyA based 1033 49.1 816 49.0 217 49.9
Tac based 1069 50.9 851 51.0 218 50.1 0.73
Year of HCT ≤2008 1107 52.7 875 52.5 232 53.3
≥2009 995 47.3 792 47.5 203 46.7 0.75
Follow-up period Median 1134 1130 1171.5 0.11
(Range) (40–4947) (40–4922) (41–4947)
CY cyclophosphamide, TBI total-body irradiation, HDCA high-dose cytarabine, PS performance status, HCT-CI hematopoietic cell transplant co-morbidity index,
CMV cytomegalovirus, AML acute myelogenous leukemia, MDS myelodysplastic syndrome, Rel related donor, UR unrelated donor, BM bone marrow graft,
PB peripheral blood stem cell graft, NCC nucleated cell count, HLA human leukocyte antigen, M to F male to female, F to M female to male, GVHD graft-versus-host
disease, CyA cyclosporine, Tac tacrolimus
*Indicates statistically significant by the χ2 test or Student’s t test
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37.5 vs 37.7 %, respectively) (Fig. 2). Hemorrhagic cystitis,
mostly due to viral reactivation or infection [11], and
thrombotic microangiopathy (TMA) were more fre-
quently observed in the HDCA/CY/TBI group (HR, 1.47;
p = 0.06, and HR, 1.60; p = 0.04, respectively). These two
Fig. 1 Prognosis after HCT in each group of the conditioning
regimen. a OS was calculated with the Kaplan-Meier method in
each group of HDCA/CY/TBI and CY/TBI. HR for overall mortality of
HDCA/CY/TBI compared to CY/TBI was calculated by Cox proportional
hazards model after being adjusted for confounding factors such
as patient sex, age, PS, CMV sero-status, diagnosis, disease risk,
days from diagnosis to HCT, HLA mismatch, sex mismatch, and
year of HCT. b Tumor-related mortality, defined as death without
remission or after relapse, was calculated using Gray’s method
considering therapy-related death as a competing risk. HR was
calculated by using Fine-Gray proportional hazards model adjusted
by the confounding factors mentioned above. c NRM was calculated
using Gray’s method considering relapse as a competing risk. HR was
also calculated using the same model
Table 2 Univariate analysis of prognosis
Variables Overall mortality
HR (95 % CI) p
Conditioning CY/TBI (Reference)
HDCA/CY/TBI 1.50 (1.29–1.74) <0.01*
Other variables
Sex Female (Reference)
Male 1.00 (0.88–1.14) 0.96
Age ≤49 (Reference)
≥50 1.93 (1.65–2.25) <0.01*
PS 0–1 (Reference)
≥2 2.20 (1.74–2.80) <0.01*
HCT-CI ≤2 (Reference)
≥3 1.90 (1.46–2.47) <0.01*
CMV sero-status Negative (Reference)
Positive 1.24 (1.04–1.48) 0.02*
Diagnosis AML (Reference)
MDS 0.61 (0.49–0.75) <0.01*
Disease risk Standard (Reference)
High 2.38 (2.10–2.71) <0.01*
Days from diagnosis to HCT ≤240 (Reference)
≥241 0.89 (0.78–1.01) 0.08
Donor Rel-BM (Reference)
Rel-PB 1.16 (0.96–1.40) 0.13
UR-BM 1.11 (0.95–1.31) 0.20
HLA mismatch Matched (Reference)
Mismatched 1.25 (1.01–1.43) <0.01*
Sex mismatch Matched (Reference)
M to F 1.04 (0.89–1.22) 0.60
F to M 1.16 (0.99–1.36) 0.07
ABO mismatch Matched (Reference)
Minor 0.90 (0.75–1.07) 0.23
Major 1.11 (0.93–1.32) 0.23
Both 0.83 (0.64–1.07) 0.15
GVHD prophylaxis CyA based (Reference)
Tac based 1.01 (0.89–1.15) 0.87
Year of HCT ≤2008 (Reference)
≥2009 0.86 (0.75–0.99) 0.04*
Other abbreviations are explained in Table 1
HR hazard ratio, CI confidence interval
*Indicates statistically significant
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complications were related to a significantly higher pro-
portion of NRM (data not shown). Other potential com-
plications of HDCA, such as central nervous system
(CNS) dysfunction and acute respiratory dysfunction syn-
drome (ARDS) [12], were not increased in the HDCA/
CY/TBI group.
Discussion
In this study on myeloablative BMT/PBSCT for AML/
MDS, we did not observe the improvement of OS in the
HDCA/CY/TBI group due to (1) a higher proportion of
NRM and (2) the lack of apparent additional anti-leukemic
effect of HDCA. These results differ from those of CBT, in
which a stronger anti-leukemic effect without increased
NRM led to superior OS in HDCA/CY/TBI [5].
Among acute phase complications that can lead to
NRM, hemorrhagic cystitis and TMA were increased
after HDCA/CY/TBI. These complications, if not re-
solved early, can induce renal failure, prohibit immune
reconstitution, and deteriorate patient’s nutrition and
performance status, which may ultimately lead to
significantly higher NRM [11, 13]. The strong cytotoxicity
of HDCA combined with significantly poorer neutrophil
engraftment might cause cystitis-related virus reactivation
or vascular endothelial cell injury which can induce
hemorrhagic cystitis or TMA. These features were not ob-
served in CBT [5]; the relatively higher incidence of acute
GVHD in BMT/PBSCT can explain this difference because
both hemorrhagic cystitis and TMA are closely related to
preceding acute GVHD [11, 13].
On the other hand, no additional anti-leukemic effect
of HDCA was apparent in this study. HDCA can reduce
the remaining leukemia cells that may cause relapse after
HCT [12]. This anti-leukemic effect of HDCA directly
reduced the incidence of relapse in CBT [5] because
graft-versus-leukemia (GVL) effects after CBT was rela-
tively weak [14]; relapse after CBT mainly depends on
the efficacy of conditioning regimens [5]. In BMT/
PBSCT, however, GVL effects are much stronger than
CBT especially in the case of HLA-mismatched trans-
plantation [14]. Suppression of total relapse after
HCT is mainly attributed to continuous GVL effects [14]
Table 3 Multivariate analysis of prognosis in patients with HDCA/CY/TBI compared with CY/TBI
Variables Overall mortality Tumor-related mortality NRM
HR (95 % CI) p HR (95 % CI) p HR (95 % CI) p
Conditioning CY/TBI (Reference) (Reference) (Reference)
HDCA/CY/TBI 1.14 (0.96–1.34) 0.13 0.90 (0.72–1.12) 0.34 1.48 (1.15–1.91) <0.01*
Other variables
Age ≤49 (Reference) (Reference) (Reference)
≥50 1.86 (1.57–2.20) <0.01* 1.31 (1.02–1.68) 0.03* 2.04 (1.60–2.61) <0.01*
PS 0–1 (Reference) (Reference) (Reference)
≥2 1.42 (1.09–1.85) <0.01* 1.73 (1.25–2.39) <0.01* 0.71 (0.41–1.23) 0.22
CMV sero-status Negative (Reference) (Reference) (Reference)
Positive 1.12 (0.93–1.34) 0.23 1.29 (1.00–1.65) 0.05* 0.91 (0.70–1.18) 0.47
Diagnosis AML (Reference) (Reference) (Reference)
MDS 0.40 (0.32–0.51) <0.01* 0.18 (0.12–0.27) <0.01* 1.18 (0.87–1.59) 0.28
Disease risk Standard (Reference) (Reference) (Reference)
High 2.53 (2.18–2.93) <0.01* 3.98 (3.26–4.85) <0.01* 0.97 (0.77–1.23) 0.82
Days from diagnosis to HCT ≤240 (Reference) (Reference) (Reference)
≥241 0.88 (0.76–1.01) 0.07 0.80 (0.66–0.97) 0.02* 0.98 (0.79–1.22) 0.89
HLA mismatch Matched (Reference) (Reference) (Reference)
Mismatched 1.25 (1.08–1.44) <0.01* 0.90 (0.73–1.10) 0.30 1.60 (1.29–1.99) <0.01*
Sex mismatch Matched (Reference) (Reference) (Reference)
M to F 0.97 (0.81–1.15) 0.70 0.91 (0.72–1.15) 0.44 1.01 (0.77–1.31) 0.97
F to M 1.12 (0.94–1.33) 0.20 0.94 (0.74–1.20) 0.63 1.28 (0.99–1.65) 0.07
Year of HCT ≤2008 (Reference) (Reference) (Reference)
≥2009 0.89 (0.77–1.02) 0.10 0.96 (0.80–1.16) 0.70 0.76 (0.61–0.94) 0.01*
Other abbreviations are explained in Tables 1 and 2
NRM non-relapse mortality
*Indicates statistically significant
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compared to the conditioning regimens which will be inac-
tivated rapidly after HCT [12]; strength of conditioning
regimens (for example, HDCA addition in this study) may
not directly influence on relapse reduction. These differ-
ences in GVL effects can partly explain the discrepancy in
the efficacy of HDCA on post-transplant relapse or
disease-related death.
A larger proportion of patients with high-risk disease
and worse performance status in the HDCA/CY/TBI
group may confound the outcomes, but multivariate and
subgroup analyses indicated unimproved prognosis in
HDCA/CY/TBI even after eliminating those confounding
factors. Moreover, subgroup analyses regarding the per-
centage of myeloblast just before conditioning regimens
were carried out; no significant differences of OS between
CY/TBI and HDCA/CY/TBI were found in any subgroups
(data not shown). The bias in regard to the HCT centers,
however, still remains to be overcome in this study. The
choice of conditioning regimen depends on the at-
tending physicians in each institution, indicating that
the clinical experiences of each transplant center can
be a confounding factor. Unfortunately, we were not
able to adjust this factor because the database did
not contain such information.
The combination of granulocyte colony stimulating
factor (G-CSF) with HDCA is another important topic;
it is reported that G-CSF-combined HDCA/CY/TBI pro-
vided low NRM and high OS in a previous study [15]. In
our cohort, patients with G-CSF-combined HDCA/CY/
TBI regimen (N = 25) revealed almost the same progno-
sis (HR, 1.02; 95 %CI, 0.59–1.76; p = 0.95) as HDCA/
CY/TBI without G-CSF.
In summary, this study showed the inefficacy of adding
HDCA to CY/TBI in BMT/PBSCT for AML/MDS, sug-
gesting that the merits of HDCA in CBT cannot be ex-
trapolated to BMT/PBSCT. Incidence of GVHD or
strength of GVL effects may be related to these differ-
ences between donor sources. This single-country retro-
spective analysis should be validated in future
prospective studies in order to determine proper condi-
tioning regimens in BMT/PBSCT for AML/MDS.
Additional file
Additional file 1: Figure S1. Subgroup analyses of OS with respect to
patient characteristics. OS was compared in each subgroup with respect
to patient characteristics. The adjusted HRs of overall mortality in the
HDCA/CY/TBI group were shown compared to the CY/TBI group. Black
dots indicate HRs, and 95 %CI ranges are shown by black bars.
Table 4 Causes of NRM
Cause of NRM Total CY/TBI HDCA/CY/TBI
N % N % N % p
Infection 110 27.3 78 26.4 32 29.6 0.52
Bacteria 61 43 18
Virus 19 14 5
Fungi 13 9 4
Rejection/engraftment failure 3 0.7 3 1.0 0 0.0 0.29
TMA 10 2.5 8 2.7 2 1.9 0.62
VOD 15 3.7 12 4.1 3 2.8 0.54
GVHD 44 10.9 32 10.8 12 11.1 0.94
Acute 20 14 6
Chronic 24 18 6
Hemorrhage 24 6.0 18 6.1 6 5.6 0.84
Organ failure 127 31.5 95 32.2 32 29.6 0.62
Liver 9 7 2
Heart 13 8 5
Kidney 6 4 2
CNS 8 6 2
Lung 82 62 20
Interstitial pneumonia 40 29 11
ARDS 14 13 1
Secondary malignancy 1 0.2 1 0.3 0 0.0 0.54
Others 69 17.1 48 16.3 21 19.4
Total 403 100.0 295 100.0 108 100.0
Other abbreviations are explained in Tables 1–3
TMA thrombotic microangiopathy, VOD veno-occlusive disease, CNS central
nervous system, ARDS acute respiratory distress syndrome
Fig. 2 Clinical courses after HCT in each group of CY/TBI and HDCA/
CY/TBI. The cumulative incidence of major clinical events after HCT,
such as engraftment, GVHD, infection, and other acute phase
complications are summarized. In each event, adjusted HRs in
the HDCA/CY/TBI group were analyzed in comparison with the
CY/TBI group. Dots indicate HRs, and bars indicate 95 % CI ranges
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Abbreviations
AML: acute myelogenous leukemia; BMT: bone marrow transplantation;
CBT: cord blood transplantation; CI: confidence interval; CY: cyclophosphamide;
GVHD: graft-versus-host disease; GVL: graft versus leukemia; HCT: hematopoietic
cell transplantation; HDCA: high-dose cytarabine; HLA: human leukocyte antigen;
HR: hazard ratio; MDS: myelodysplastic syndrome; NRM: non-relapse
mortality; OS: overall survival; PBSCT: peripheral blood stem cell transplantation;
Rel: related donor; TBI: total-body irradiation; TMA: thrombotic microangiopathy;
UR: unrelated donor.
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